This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
02/11/16 - 3:19:13 PM ET (BATS BZX Real-time Price)
Div Yield: --
CUR Day's Range
CUR 52 Week Range
CUR Business Summary
Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of regenerative medicine treatments based on its human neuronal stem cells and small molecule compounds.View CUR
Neuralstem Inc - CUR - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Neuralstem Inc as a
Sell with a ratings score of D-.
Report Snippet: We rate NEURALSTEM INC (CUR) a SELL. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally high debt management risk and generally disappointing historical performance in the stock itself.